Medpace Holdings jumps as Q2 results and outlook top expectations

Medpace Holdings (MEDP) is up 17.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The sharp move appears tied to a strong second-quarter report that showed solid revenue growth, higher earnings, improved bookings, and a raised full-year outlook. Investors also seemed encouraged that net new business awards rebounded enough to push book-to-bill above 1.0x, easing some recent concern about cancellations and backlog quality.

Details:

Second-quarter revenue rose 17.2% year over year to $707.3 million, while diluted earnings per share increased to $4.25 from $3.10.

Net new business awards reached $795.7 million, up 28.2% from a year earlier, and the quarter’s net book-to-bill ratio improved to 1.13x.

Backlog at June 30, 2026 was $3.01 billion, up 4.9% from a year earlier, suggesting demand held up better than some investors had feared.

Management lifted 2026 guidance to revenue of $2.805 billion to $2.885 billion and diluted EPS of $17.25 to $17.95, up from prior ranges of $2.755 billion to $2.855 billion and $16.68 to $17.50.

Sources:

Medpace Holdings, SEC, MarketBeat

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MEDP Insider Trading Activity

$MEDP insiders have traded $MEDP stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $MEDP stock by insiders over the last 6 months:

JESSE J GEIGER (President) sold 31,707 shares for an estimated $14,436,197
STEPHEN P EWALD (General Counsel & Corp. Secy.) sold 16,349 shares for an estimated $7,357,050

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive MEDP Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$MEDP Hedge Fund Activity

We have seen 285 institutional investors add shares of $MEDP stock to their portfolio, and 378 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

GOLDMAN SACHS GROUP INC removed 178,562 shares (-51.5%) from their portfolio in Q1 2026, for an estimated $85,743,686
FINDLAY PARK PARTNERS LLP removed 174,400 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $83,745,136
PRICE T ROWE ASSOCIATES INC /MD/ added 172,926 shares (+148.3%) to their portfolio in Q1 2026, for an estimated $83,037,335
JONES FINANCIAL COMPANIES LLLP added 167,185 shares (+16553.0%) to their portfolio in Q1 2026, for an estimated $80,280,565
VULCAN VALUE PARTNERS, LLC added 155,762 shares (+329.3%) to their portfolio in Q1 2026, for an estimated $74,795,354
QUBE RESEARCH & TECHNOLOGIES LTD removed 146,673 shares (-95.4%) from their portfolio in Q1 2026, for an estimated $70,430,907
WASATCH ADVISORS LP removed 137,336 shares (-17.7%) from their portfolio in Q2 2026, for an estimated $72,731,772

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$MEDP Congressional Stock Trading

Members of Congress have traded $MEDP stock 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $MEDP stock by members of Congress over the last 6 months:

REPRESENTATIVE DAVID TAYLOR has traded it 4 times. They made 4 purchases worth up to $60,000 on 05/15, 02/26, 01/29 and 0 sales.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$MEDP Analyst Ratings

Wall Street analysts have issued reports on $MEDP in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Jefferies issued a "Buy" rating on 02/13/2026

To track analyst ratings and price targets for $MEDP, check out Quiver Quantitative's $MEDP forecast page.

$MEDP Price Targets

Multiple analysts have issued price targets for $MEDP recently. We have seen 8 analysts offer price targets for $MEDP in the last 6 months, with a median target of $484.5.

Here are some recent targets:

Eric Coldwell from Baird set a target price of $547.0 on 07/08/2026
David Windley from Jefferies set a target price of $515.0 on 07/07/2026
Ryan Halsted from RBC Capital set a target price of $484.0 on 04/24/2026
Sean Dodge from BMO Capital set a target price of $400.0 on 04/24/2026
Luke Sergott from Barclays set a target price of $450.0 on 04/24/2026
Charles Rhyee from TD Cowen set a target price of $419.0 on 02/18/2026
Michael Cherny from Leerink Partners set a target price of $485.0 on 02/11/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.